Abstract
AbstractIn general, only a small fraction of drug administered as eye drops enters the eye. This is due to permeability barriers of the eye as well as effective rinsing of the ocular surface. Additionally, lipophilic drug molecules are difficult to dissolve in adequate concentrations in eye drops. We have developed a drug delivery platform, based on cyclodextrins, which can be used to increase drug delivery with eye drops. The cyclodextrins are lipophilic on the inside and hydrophilic on the outside. This allows formation of water‐soluble complexes of cyclodextrins and lipophilic drug molecules, thereby increasing the possible concentration of drug in the eye drop. Cyclodextrins may also increase drug delivery by enhancing mucoadhesion and by facilitating transport of drug molecules through the unstirred water layer at the surface of the eye. We have formulated and tested cyclodextrin‐dexamethasone eye drops. The eye drops have been shown to decrease diabetic macular edema. A recent study also shows higher and extended concentration of dissolved dexamethasone after using cyclodextrin‐dexamethasone, compared to a regular formulation of dexamethasone. Commercial interest
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
